Cardlytics Valuation
| CDLX Stock | USD 0.95 0.04 4.49% |
Despite its low share price, Cardlytics still appears fairly valued. The market is pricing it at $0.95 per share, versus an estimated Real Value of $0.94. For Cardlytics, the model's primary valuation inputs include current valuation of $211.79M and a return on equity of -3.26%, with an added check on probability of bankruptcy. Key valuation drivers for Cardlytics include:
At present, Cash is moving upward relative to prior years. As of the last annual report, Cash was 48.72 Million. As of earlier this week, Change To Account Receivables is projected to grow to approximately 21.7 M, while Accounts Payable is moving lower toward about 3.3 M.
Price Book 1.5779 | Enterprise Value | Enterprise Value Ebitda -7.69 | Price Sales 0.2151 | Enterprise Value Revenue 0.9079 |
Fairly Valued
Today
Current trading conditions suggest that Cardlytics' price fluctuation is Abnormal right now. For valuation purposes, Macroaxis measures Cardlytics over a 3 months time horizon. A broader horizon usually helps the model produce a more dependable value estimate over time.
Because the shares are exchange-traded, the market value of Cardlytics Stock is established by buyers and sellers in real time. Price can deviate from underlying value, and that disconnect may become relevant if the market later re-prices the asset more efficiently. | Historical | Market 0.95 | Real 0.94 | Target 1.04 | Hype 0.91 | Naive 0.88 |
The intrinsic value of Cardlytics is the estimate of Cardlytics' true worth based on financial fundamentals. Alternative valuation methods like price-to-earnings or price-to-book can also approximate Cardlytics' fair value. The intrinsic value gives investors a target price range anchored in business fundamentals. Financial performance, growth prospects, and competitive position together determine Cardlytics' intrinsic value.
Measuring the upside and downside potential of Cardlytics gives a realistic sense of possible returns. Forecasting how Cardlytics stock performs depends on integrating fundamentals and market-based signals. Understanding the full range of upside and downside possibilities supports better investment decisions. In addition to Cardlytics' fundamentals, the valuation considers technical factors and macro trends.The valuation of Cardlytics depends on its stage of development, asset intensity, and cash flow profile. A disciplined investor reconciles outputs of different methods to arrive at a realistic Cardlytics' fair value. Comparing Cardlytics's valuation across multiple methods provides a sanity check on the estimate. Benchmarking against peers produces the most actionable estimate of Cardlytics' value.
Main Profitability Drivers
Cardlytics reports a net profit margin of -44.36% alongside an operating margin of -9.87%. A 34.49-point margin gap suggests that below-the-line items meaningfully affect Cardlytics' net profitability. Revenue of 233.27 Million translated into 104.61 Million of gross profit for Cardlytics, with net income reaching -103.49 Million. Return on equity is -3.26% and return on assets is -8.69%, providing a view of how efficiently Cardlytics' capital and asset base are deployed. Cardlytics' profitability trends show broad deterioration, with the majority of key metrics declining year over year. A more granular view is available in Cardlytics' profitability metrics for a broader perspective on earnings quality.
Price Book 1.5779 | Gross Profit | Price Sales 0.2151 | Profit Margin | Enterprise Value Revenue 0.9079 |
Cardlytics Cash | 46.28 Million |
Total Value Analysis
The current total-value analysis for Cardlytics points to enterprise value near 211.79 M, market capitalization around 50.19 M, debt of 215.31 M, and cash balances of 157.04 M. Investors should review Cardlytics fundamentals before making decisions based too heavily on enterprise value alone.| Takeover Price | Market Cap | Debt Obligations | Cash |
211.79 M | 50.19 M | 215.31 M | 157.04 M |
Investor Information
About 40.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.58. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cardlytics recorded a loss per share of 1.95. The company had not issued any dividends in recent years. Current financial indicators suggest pressured financial positioning in asset utilization and capital deployment. The earnings picture reflects near-term margin compression relative to deployed assets.Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cardlytics has an asset utilization ratio of 81.67 percent. This suggests that the Company is making $0.82 for each dollar of assets. An increasing asset utilization means that Cardlytics is more efficient with each dollar of assets it utilizes for everyday operations.Macro event markers
Profitability Analysis
Based on Cardlytics' profitability indicators, Cardlytics may not be well positioned to generate adequate gross income at the present time. It has a very high likelihood of underperforming in April. Profitability indicators assess Cardlytics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2015-06-30 | Previous Quarter -72.7 M | Current Value -8.2 M | Quarterly Volatility 63.5 M |
Macro event markers
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.3 | 0.4505 |
|
|
The profitability module for Cardlytics is designed to show how the business generates income relative to revenue, assets, expenses, and shareholder capital. These profitability indicators help investors judge how well Cardlytics uses its assets to create earnings power and long-term shareholder value. Cardlytics currently reports return on equity near -3.26%, which helps anchor profitability expectations.
Earnings per Share Projection vs Actual
Comparing Cardlytics' estimated and trailing EPS clarifies whether the earnings trajectory is accelerating or decelerating. Comparing forward and trailing EPS signals whether the earnings trajectory is expanding or contracting. Margin trends and working capital shifts add nuance to Cardlytics' reported EPS. Estimate dispersion for Cardlytics reflects the degree of uncertainty embedded in current analyst models. Consensus earnings estimates for Cardlytics should be reviewed carefully because analyst EPS forecasts are usually built before non-recurring items and option-related expenses are fully unpacked. Cardlytics is projected to generate -0.195 in earnings per share on 30th of June 2026. The practical value of the EPS estimate is that it gives investors a benchmark for comparing reported results with the market's prior expectations.Macro event markers
Ownership Allocation
About 30% of Cardlytics outstanding shares are owned by institutional holders. Institutional investors - such as mutual funds, pension funds, and asset managers - typically hold positions as part of a broader portfolio strategy, managing assets on behalf of clients. As a result, institutional investors are subject to reporting requirements and oversight rules - such as 13F filings - that differ from those for individual retail investors. Changes in institutional ownership of Cardlytics can sometimes signal a shift in professional sentiment toward the company. The 40% institutional stake in Cardlytics compares to 3% held by insiders and 57% by retail investors.Revenue and Profit Overview
The company reported previous year's revenue of 233.27 M. Net Loss for the year was -103.49 M with profit before overhead, payroll, taxes, and interest of 104.61 M.Valuation analysis for Cardlytics should be treated as an ongoing process rather than a one-time answer, especially when investors are trying to understand how the market is pricing this stock. This becomes more informative when investors compare operating progress, market capitalization, and expected business performance in the same review.
Valuation Framework, Methodology & Assumptions
Cardlytics is a micro-cap equity in Advertising, Media & Entertainment, Communication Services categories. Capital structure affects intrinsic modeling assumptions. For Cardlytics, the leading valuation metrics are P/S of 0.22, enterprise value of 211.79 M; additional context comes from P/B of 1.58.
Unless otherwise specified, data for Cardlytics is compiled from periodic company reporting and market reference feeds and standardized for comparability. Updates may occur throughout the day. Valuation outputs are model-derived and depend on published assumptions and reference inputs.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial BoardGrowth Indicators
Growth investing in Cardlytics can be rewarding, but it usually depends on the market continuing to believe in above-average sales and earnings expansion. Used properly, growth analysis separates durable compounding from optimism that may already be fully priced in.
| Common Stock Shares Outstanding | 53.1 M | |
| Quarterly Earnings Growth Y O Y | -0.567 |
Cardlytics Current Valuation Indicators
Valuation of Cardlytics is strongest when several lenses are used together: market cap, enterprise value. revenue, and cash-flow durability. Good valuation narrows the range of reasonable outcomes before capital is committed.
Popular Tools for Cardlytics Stock analysis
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |